ABBOTT has secured an exclusive
license for several novel biomarkers
from Stanford University.
According to Abbott the novel
biomarkers will be used to aid in
the development of a molecular
diagnostic test which would
differentiate aggressive from
nonaggressive prostate cancer.
“Developing a clinically validated
prostate cancer prognostic assay
with actionable data represents the
'holy grail' in improving disease
management,” said Stanford
University Medical Centre’s James
Brooks, Associate Professor,
Department of Urology.
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 18 Apr 12
Established in 2007, Pharmacy Daily is Australia's leading pharmacy industry publication, and is sent as a free subscription to people across the industry as a PDF newsletter every weekday.
To sign up for a free subscription, click on the button at right.
